An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to <18 Years of Age With Atopic Dermatitis
Phase of Trial: Phase III
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 01 Dec 2017 Planned patient number changed to 812.
- 27 Nov 2017 Planned number of patients changed from 69 to 765.
- 27 Nov 2017 Planned End Date changed from 1 Oct 2018 to 16 Oct 2023.